Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Organic Cation Transporters (OCT1, OCT2, OCT3) and Multidrug and Toxin Extrusion proteins (MATE1, MATE2-K) constitute a coordinated vectorial transport system essential for the disposition of organic cations (UniProt O15245, Q96FL8). OCTs, belonging to the SLC22 family, mediate the electrogenic uptake of substrates from the blood into tissues like the liver and kidney (PMID: 23585110). MATE proteins, belonging to the SLC47 family, function as H+/organic cation antiporters that facilitate the final excretion of these substances into the bile or urine (PMID: 21312325). This system is a primary determinant of the pharmacokinetics and pharmacodynamics of numerous drugs, most notably the antidiabetic metformin and the platinum-based chemotherapeutic cisplatin. OCT2 and MATE1/2-K are particularly critical in the renal proximal tubule, where they work in tandem to clear drugs and endogenous metabolites like creatinine. Inhibition of these transporters by drugs such as cimetidine or dolutegravir can lead to significant drug-drug interactions, often manifesting as increased plasma concentrations of co-administered substrates (FDA 2020). Furthermore, genetic polymorphisms in these transporters are associated with inter-individual variability in drug efficacy and the risk of adverse effects, such as cisplatin-induced nephrotoxicity. Consequently, these transporters are key targets for evaluation during drug development to ensure safety and optimize dosing regimens.
OCTs (SLC22A1-3) function as electrogenic uniporters that facilitate the diffusion of organic cations into cells down their electrochemical gradient. MATEs (SLC47A1-2) function as H+/organic cation antiporters, utilizing the transmembrane proton gradient to efflux cations from the cytoplasm into the extracellular space, such as the renal tubule lumen or the bile canaliculi (PMID: 23585110, 21312325).
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Organic cation transporter 1, 2, 3 and multidrug and toxin extrusion protein 1, 2-K (OCT/MATE).